94 related articles for article (PubMed ID: 31134385)
1. Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Yoshida J; Ishikawa T; Doi T; Ota T; Yasuda T; Okayama T; Sakamoto N; Inoue K; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Naito Y; Itoh Y
Med Oncol; 2019 May; 36(7):60. PubMed ID: 31134385
[TBL] [Abstract][Full Text] [Related]
2. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
Yamamoto K; Makino T; Sato E; Noma T; Urakawa S; Takeoka T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Mori M; Doki Y; Wada H
Cancer Sci; 2020 Apr; 111(4):1103-1112. PubMed ID: 31981293
[TBL] [Abstract][Full Text] [Related]
4. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of circulating soluble CD226 in multiple sclerosis.
Kari S; Bucciarelli F; Angles T; Oster AC; Cauboue P; Laviolette K; Mougenot M; Morandi E; Bernard I; Pignolet B; Bost C; Thomas J; Nogueira L; Saoudi A; Liblau R; Astier AL
Mult Scler; 2024 May; 30(6):654-663. PubMed ID: 38424741
[TBL] [Abstract][Full Text] [Related]
6. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
[TBL] [Abstract][Full Text] [Related]
8. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
9. Serum Level of Soluble Lymphocyte-Activation Gene 3 Is Increased in Patients with Rheumatoid Arthritis.
Saadati N; Khodashahi M; Rezaieyazdi Z; Sahebari M; Saremi Z; Mohammadian Haftcheshmeh S; Rafatpanah H; Salehi M
Iran J Immunol; 2020 Dec; 17(4):324-332. PubMed ID: 33382389
[TBL] [Abstract][Full Text] [Related]
10. TIGIT in cancer immunotherapy.
Chauvin JM; Zarour HM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
[TBL] [Abstract][Full Text] [Related]
11. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients.
Machiraju D; Wiecken M; Lang N; Hülsmeyer I; Roth J; Schank TE; Eurich R; Halama N; Enk A; Hassel JC
Oncoimmunology; 2021 May; 10(1):1926762. PubMed ID: 34104542
[TBL] [Abstract][Full Text] [Related]
12. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
Zhou X; Ren T; Zan H; Hua C; Guo X
Front Immunol; 2022; 13():864202. PubMed ID: 35669786
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma.
Gebauer F; Krämer M; Bruns C; Schlößer HA; Thelen M; Lohneis P; Schröder W; Zander T; Alakus H; Buettner R; Loeser H; Quaas A
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2319-2327. PubMed ID: 32592066
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.
Kgokolo MCM; Malinga NZ; Steel HC; Meyer PWA; Smit T; Anderson R; Rapoport BL
Transl Oncol; 2024 Apr; 42():101867. PubMed ID: 38308919
[TBL] [Abstract][Full Text] [Related]
16. The predictive role of soluble programmed death ligand 1 in digestive system cancers.
Ruan J; Zhao Z; Qian Y; Xu R; Liao G; Kong FS
Front Oncol; 2023; 13():1170220. PubMed ID: 37519785
[TBL] [Abstract][Full Text] [Related]
17. Kinesin family member 23 knockdown inhibits cell proliferation and epithelial-mesenchymal transition in esophageal carcinoma by inactivating the Wnt/β-catenin pathway.
Xu Q; Li X; Li Y; Yu J; Yang A
Funct Integr Genomics; 2023 May; 23(2):154. PubMed ID: 37162618
[TBL] [Abstract][Full Text] [Related]
18. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
Du J; Yang Y; Zhu L; Wang S; Yu C; Liu C; Long C; Chen B; Xu G; Zou L; Wang L
Heliyon; 2023 Mar; 9(3):e13999. PubMed ID: 36915535
[TBL] [Abstract][Full Text] [Related]
19. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis.
Zhang D; Liu J; Zheng M; Meng C; Liao J
World J Surg Oncol; 2022 Oct; 20(1):351. PubMed ID: 36309698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
